Case Page

 

Case Status:    DISMISSED    
On or around 03/02/2016 (Other)

Filing Date: June 24, 2014

According to the law firm press release, the complaint arises out of false and misleading statements regarding the efficacy of Endocyte's experimental drug, VYNFINIT®. The complaint alleges that during the Class Period, certain of Endocyte's officers issued materially false and misleading statements regarding the Company's business prospects. Specifically, on March 21, 2014, Endocyte issued a press release announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued "positive opinions" for the "Conditional Marketing Authorisations" for the drug VYNFINIT®, used to treat platinum-resistant ovarian cancer ("PROC") with VYNFINIT® using testing methods known as response evaluation criteria in solid tumors ("RECIST"). Endocyte failed to disclose that the "positive opinions" were based on the testing criteria called RECIST 1.0 while the pending analysis for the "Conditional Marketing Authorisations" would be using the more stringent RECIST 1.1 testing criteria. As a result of the defendants' false statements, on March 21, 2014, Endocyte's stock jumped 92%, from $14.64 to $28.17. The complaint further alleges that, in an attempt to take advantage of the Company's stock jump following the March 21 press release, Endocyte issued a public offering to quickly sell shares at the inflated price. By April 2, 2014 the Company issued over 5 million shares, and acquired a net proceed of approximately $101.8 million.

On May 2, 2014 the Company announced that VYNFINIT® was found ineffective in the treatment of PROC based on RECIST 1.1. Upon this announcement, on May 2, 2014, Endocyte stock dropped over 61%, from $17.38 to close at $6.62. On May 19, 2014 the company then announced that it would withdraw its application to sell VYNFINIT® in Europe. The omitted and/or misrepresented information is believed to be material to potential Endocyte's shareholders' ability to make an informed decision whether to purchase Endocyte stock.

On January 4, 2016, the Court issued an Order dismissing the Plaintiff's complaint without prejudice. Plaintiffs did not file an amended complaint, thus this case was dismissed with prejudice on February 2.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ECYT
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. Indiana
DOCKET #: 14-CV-01048
JUDGE: Hon. Tanya Walton Pratt
DATE FILED: 06/24/2014
CLASS PERIOD START: 03/21/2014
CLASS PERIOD END: 05/02/2014
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Lewis Wagner LLP
    501 Indiana Avenue, Lewis Wagner LLP, IN 46202
    317.237.0500 317.630.2790 ·
  2. Robbins Arroyo LLP
    600 B Street, Suite 1900, Robbins Arroyo LLP, CA 92101
    619.525.3990 619.525.3991 ·
No Document Title Filing Date
COURT: S.D. Indiana
DOCKET #: 14-CV-01048
JUDGE: Hon. Tanya Walton Pratt
DATE FILED: 11/17/2014
CLASS PERIOD START: 03/21/2014
CLASS PERIOD END: 05/02/2014
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Kahn Swick & Foti, LLC (Madisonville)
    206 Covington Street, Kahn Swick & Foti, LLC (Madisonville), LA 70447
    (504) 455-1400 (504) 455-1498 ·
No Document Title Filing Date